Zusammenfassung
Weltweit sind beträchtliche Unterschiede in der Morbidität und Mortalität des Prostatacarcinoms bekannt. Die höchste Inzidenz besteht bei der schwarzen Bevölkerung in den USA, Asiaten hingegen erkranken nur sehr selten.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Silverberg E (1987) Cancer 60 (Suppl): 692–717
Oremek G, Seiffert UB et al. (1987) Diagnostik und Verlaufskontrolle urologischer Tumorerkrankungen durch den Einsatz von Tumormarkern. Lab Med 11: 180
Oremek G, Seiffert UB et al. (1986) Welche analytische Methode zur Bestimmung der sauren Phosphatase (SP) beziehungsweise Prostataphosphatase (PAP) sollte im Routinelabor angewendet werden? Lab Med 10: 171
Siede W, Oremek G, Seiffert UB (1987) Tumormarker Medwelt 38: 1113–18
Spitz J, Clemenz N (1987) Vergleichende Untersuchungen Radioimmunoassays zur Bestimmung des prostataspezifischen Antigens (PSA). Lab Med 7 /8: 342
Wirth M (1986) Diagnostik und Verlaufskontrolle urologischer Karzinome: Wertigkeit verschiedener Tumormarker. Diagnose Labor 36: 75
Bostwick DG, Brawer MK (1987) Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 59: 788–794
Helpap B (1980) The biological significance of atypical hyperplasia of the prostate. Virchows Arch A 387: 307–317
Mc Neal JE, Bostwick DG (1986) Intraductal dysplasia. A pre- malignant lesion of the prostate. Human Pathol 17: 64–71
Jacobi GH, Wenderoth UK (1982) Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension. Eur Urol 8: 129–134
Labrie F et al. (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579–594
Schroeder FH et al. (1987) Metastatic cancer of the prostate managed with Buserelin versus Buserelin plus Cyproterone acetate. J Urol Vol 137: 912–918
Wenderoth UK, Jacobi GH (1985) Langzeitergebnisse mit dem Gn-RH-Analogon Buserelin (Suprefact) bei der Behandlung des fortgeschrittenen Prostatakarzinoms seit 1981. Akt Urol 16: 58–63
Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R (1982) Sustained suppression of testosterone production by the luteneising-hormone releasing hormone agonist buselerin in patients with advanced prostate carcinoma. A new therapeutic approach. Lancet II: 1097
Debruyne FMJ, Karthaus HFM, Schröder FH, De Voogt HJ, De Jong FH, Klijn JGM (1985) Results of a Dutch phase II trial with the LHRH agonist Buserelin in patients with metastatic prostatic cancer. In: Schröder FH, Richards B (eds) Therapeutic principles in metastatic prostatic cancer. Liss, New York, pp 251
Denis L, Mahler C, Debruyne F, Lunglmayr G, Newling D, Richards B, Robinson M, Smith P, Whelan P (1986) Longterm results with depot LHRH analogue in patients with advanced prostatic cancer. In: Kuss R, Murphy G, Chatelain C, Khoury S, Denis L (eds) Second International Conference on Prostatic Cancer. Liss, New York
Kerle D, Williams G, Ware H, Bloom SR (1984) Failure of long-term luteinizing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. Br Med J 289: 468
Murphy GP, Beckley S, Brady MF et al. (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264
Presant CA, Soloway MS, Klioze SS, Kosola JW, Yakabow AL, Mendez RG, Kennedy PS, Wyres MR, Neassig VL, Ford KS (1985) Buserelin as primary therapy in advanced prostatic carcinoma. Cancer 56: 2416
Robinson MRG, Denis L, Mahler C, Walker K, Stitch R, Lunglmayer G (1985) An LHRH analogue (Zoladex) in the management of carcinoma of the prostate. A preliminary report comparing daily injections with monthly depot injections. Eur J Surg Onc 11: 159
Schröder FH, Lock TMTW, Chadha DR, Debruyne FMJ, de Jong FH, Klijn JGM, Matroos AW, De Voogt HJ (1987) Metastatic cancer of the prostate managed by Buserelin (HOE 766) versus Buserelin plus cyproterone acetate ( CPA ). J Urol 131: 912–918
Smith JA, jr (1984) Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J Urol 131: 1110
Trachtenberg J (1983) The treatment of metastatic prostatic cancer with a potent luteinizing-hormone releasing-hormone analogue. J Urol 129: 1149
Einhorn LH (1983) An overview of chemotherapeutic trials in advanced cancer of the prostate. In: Skinner DJ (ed) Urologi-cal cancer. Grune & Stratton, New York, pp 89–100
Logothetis CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE (1982) Doxorubicin, Mitomycin and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: A preliminary report. Cancer Treat Rep 66: 57–63
Smalley RV, Bartolucci AA, Hemstreet G, Hester M (1981) A phase II evaluation of a 3-drug combination of Cyclophosphamide, Doxorubicin and 5-Fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125: 191–195
Brindle JS, Benson RC, Martinez A, Edmundson GK, Zincke H, Utz DC (1985) Urology 25: 233–238
Herr HW (1983) In: Cancer of the prostate. Clinics in oncology vol 2. Saunders, Philadelphia
Holm HH, Juul N, Hansen H, Stroyer I (1983) J Urol 130: 283–289
Sommerkamp H, Knüfermann H, Wannenmacher M (1987) Tumordiagn Therapie 8: 16–21
Sommerkamp H, Knüfermann H, Wannenmacher M (1987) Tumordiagn Therapie 8: 22–27
Seyd AM, Puthawala A, Tansey LA, Shanberg AM, Neblett D, Mendez R, Barloon JW, Ingram JE, Naftel WT, McNamara C (1983) Radiology 149: 829–842
Bressel M (1986) Spätergebnisse nach radikaler Prostatektomie. Verhandlb Dtsch Ges Urologie 38: 230
Zincke H, Utz DC, Taylor WF (1986) Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135: 1199–1205
Aumüller G, Oksche A, Vollrath L (1979) Prostate gland and seminal vesicles. Springer, Berlin Heidelberg New York
Kastendieck H (1977) Ultrastrukturpathologie der menschlichen Prostatadrüse.In: Veröffentlichungen aus der Pathologie 106. Fischer, Stuttgart New York
Pierrepoint CG, Davies P, Lewis MH, Moffat DB (1975) J Re-prod Fert 44: 395
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Seitz, G. et al. (1988). Postersitzung 2: Das metastasierte Prostatakarzinom. In: Ackermann, R. (eds) Tagung 14.–17. Oktober 1987, Stuttgart. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83404-2_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-83404-2_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19042-4
Online ISBN: 978-3-642-83404-2
eBook Packages: Springer Book Archive